ChAd155-RSV vaccine is immunogenic and efficacious against bovine RSV infection-induced disease in young calves

Rineke Jong, Norbert Stockhofe-Zurwieden, Judith Bonsing, Kai-Fen Wang, Sarah Vandepaer, Badiaa Bouzya, Jean-François Toussaint, Ilse Dieussaert, Haifeng Song () and Ann-Muriel Steff ()
Additional contact information
Rineke Jong: Wageningen Bioveterinary Research, Wageningen University & Research
Norbert Stockhofe-Zurwieden: Wageningen Bioveterinary Research, Wageningen University & Research
Judith Bonsing: Wageningen Bioveterinary Research, Wageningen University & Research
Kai-Fen Wang: GSK
Sarah Vandepaer: CONSULTYS Benelux S.A
Badiaa Bouzya: GSK, Rue de l’Institut 89
Jean-François Toussaint: GSK, Rue de l’Institut 89
Ilse Dieussaert: GSK, Rue de l’Institut 89
Haifeng Song: GSK
Ann-Muriel Steff: GSK

Nature Communications, 2022, vol. 13, issue 1, 1-14

Abstract: Abstract Respiratory syncytial virus (RSV) infection causes a substantial lower-respiratory-tract disease burden in infants, constituting a global priority for vaccine development. We evaluated immunogenicity, safety and efficacy of a chimpanzee adenovirus (ChAd)-based vaccine candidate, ChAd155-RSV, in a bovine RSV (bRSV) challenge model. This model closely reproduces the pathogenesis/clinical manifestations of severe pediatric RSV disease. In seronegative calves, ChAd155-RSV elicits robust neutralizing antibody responses against human RSV. Two doses protect calves from clinical symptoms/lung pathological changes, and reduce nasal/lung virus loads after both a short (4-week) and a long (16-week) interval between last immunization and subsequent bRSV challenge. The one-dose regimen confers near-complete or significant protection after short-term or long-term intervals before challenge, respectively. The presence of pre-existing bRSV-antibodies does not affect short-term efficacy of the two-dose regimen. Immunized calves present no clinical signs of enhanced respiratory disease. Collectively, this supports the development of ChAd155-RSV as an RSV vaccine candidate for infants.

Date: 2022
References: View references in EconPapers View complete reference list from CitEc
Citations:

Downloads: (external link)
https://www.nature.com/articles/s41467-022-33649-3 Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:natcom:v:13:y:2022:i:1:d:10.1038_s41467-022-33649-3

Ordering information: This journal article can be ordered from
https://www.nature.com/ncomms/

DOI: 10.1038/s41467-022-33649-3

Access Statistics for this article

Nature Communications is currently edited by Nathalie Le Bot, Enda Bergin and Fiona Gillespie

More articles in Nature Communications from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().